Singapore National Eye Centre

Dear Patient/Caregiver

Please note the SNEC Pharmacy Operating Hours on Friday, 16 October 2026

SNEC (main centre): 8.30am-1.30pm
SengKang General Hospital, Bedok and Retina Centre, Diabetes and Metabolism Centre, SGH: 8.30am-1pm

For Medication Delivery Service
Click here for more information or Scan QR Code

DrZainah Corp Video
new SNEC building
SERI banner
Education corporate banner

Let Us Help

Simply tell us who you are and what you want to do below.

I’m a

Patient

Patient
Job Seeker
Visitor/Public
For Residency & Fellowship
Doctor
Donation
For Researcher
Community

looking For

Giving ＆ Philanthropy

Established in 2016, VisionSave exists to save sight and transform the lives of the underprivileged population with vision challenges. Our approach leverages philanthropic investments to pave the way for a holistic delivery of eye care.

SingVision

In this special anniversary edition of SingVision, we’re shining a light on the people and milestones that made it all possible, from progress across our 10 clinical interests, and advances in education, training, and research, to nurse-led treatments, global collaborations, and heartfelt wishes from our staff and patients.

SNEC Network of Clinics

You can now also consult with SNEC ophthalmologists at our SNEC Network of Clinics. Our specialists also perform eye surgeries at Sengkang General Hospital and Changi General Hospital, Please contact our Appointment Department for consultations or speak with our Listing Room staff for surgery scheduling.

Our Commitment to Our Patients

Our Featured Specialties

Cataract & Comprehensive Ophthalmology

Corneal & External Eye Disease

Glaucoma

Medical Retina

Neuro-ophthalmology

Ocular Inflammation & Immunology

Oculoplastic

Paediatric Ophthalmology & Adult Strabismus

Refractive Surgery

Surgical Retina

Latest News

Singapore National Eye Centre hosts its largest international ophthalmology conference at the 8th Asia-Pacific Glaucoma Congress

Announcements Singapore National Eye Centre hosts its largest international ophthalmology conference at the 8th Asia-Pacific Glaucoma Congress • New innovations in glaucoma use deep learning AI to drastically improve patient care and prevent blindness from the disease • The meeting commemorates SNEC’s 35th anniversary and achievements in Singapore’s ophthalmology scene since its founding

24 Jul 2026 Read Story

Research Formosa Pharmaceuticals and SERI Partner to Advance Novel Ophthalmic Formulations for Corneal Diseases SINGAPORE / TAIPEI — April 30, 2026 – Formosa Pharmaceuticals, Inc. (“Formosa”, 6838.TW) and the Singapore Eye Research Institute (“SERI”) are pleased to announce a strategic research collaboration to develop next-generation ophthalmic formulations. This partnership will leverage Formosa’s proprietary APNT® (Active Pharmaceutical (ingredient) Nanoparticle Technology) and SERI’s world-class clinical research expertise, led by renowned Clinician Scientist, Associate Professor Yu-Chi Liu, MD, PhD. The collaboration aims to address significant unmet needs in the treatment of corneal and ocular surface diseases. By combining innovative and clinically validated drug delivery platforms with deep clinical insights, the joint effort seeks to enhance the efficacy, bioavailability, and safety of topical ocular therapies, bringing new therapies to clinical practice. Synergy of Innovation and Clinical Excellence A/Prof Yu-Chi Liu, clinician scientist at Singapore National Eye Center and Principal Investigator at SERI, brings extensive experience in corneal neuropathy and translational medicine to the collaboration. Her recent work in diabetic keratopathy and ocular surface inflammation will be pivotal in guiding the development of formulations targeting complex anterior segment conditions. "Collaborating with Formosa Pharmaceuticals allows us to bridge the gap between benchside innovation and bedside application," said A/Prof. Yu-Chi Liu. "Our goal is to utilize advanced formulation technologies like APNT to create treatments that are not only more effective but also less burdensome for patients suffering from ocular conditions." Leveraging APNT® Technology Formosa Pharmaceuticals’ APNT® platform specializes in reducing the particle size of active pharmaceutical ingredients (APIs) to stable, uniform nanoparticles. This technology is a hallmark of Formosa's development pipeline, offering a powerful solution for improving the delivery of poorly soluble drugs to the target tissues and organs. "We are honored to work alongside Professor Liu and her distinguished team at SERI," said Erick Co, President & CEO of Formosa Pharmaceuticals. "Initial efforts have confirmed compatibility of APNT and SERI’s research models and prompt us to extend our partnership. SERI’s reputation for excellence in vision research, backed by their comprehensive capabilities and facilities, are unparalleled. Together, we are excited to translate the research findings into better clinical outcomes."

30 Apr 2026 Read Story

Education Singapore National Eye Centre and Singapore Polytechnic collaborate to strengthen optometrists’ role in community eye care The partnership will see both parties co-develop the Clinical Decision-Making in Community Optometry training programme for practicing community optometrists to build on their competencies to deliver quality eye care in the community.

05 Mar 2026 Read Story

View all news

Latest News

Singapore National Eye Centre 35th Anniversary International Meeting

24 July 2026 Read Story

Announcements Singapore Eye Research Institute tops ScholarGPS rankings in Ophthalmology The Institute has placed #1 in ophthalmology among all non-academic institutes, and #2 in the same field among all institutes, globally.

28 Jan 2026 Read Story

Announcements Singapore National Eye Centre collaborates with WHO to build eye care capability and capacity in Southeast Asia

20 Jan 2024 Read Story

View all news

Upcoming Events

View All

Singapore National Eye Centre, Global Eye Ophthalmology Unit is a designated WHO Collaborating Centre for the prevention of blindness and vision impairment.